Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Alpha Cognition Inc ACOG

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062... see more

NDAQ:ACOG - Post Discussion

Alpha Cognition Inc > $ACOG getting some major recognition from analysts
View:
Post by partystocker on Nov 04, 2021 11:26am

$ACOG getting some major recognition from analysts

Alpha Cognition Inc. $ACOG/$ACOG.V shares are recovering nicely from a small dip earlier this month. 


$ACOG’s Alzheimer's drugs are getting some serious attention from analysts. In a recent statement, Chelsea Stellick of iA Capital Markets initiated a speculative buy rating for $ACOG with a price target of $5.00 per share. At current prices of $1.19 this equates to a 420% price increase. 


$ACOG’s ALPHA-1062 Alzheimer's treatment is currently in a de-risked trial with strong data behind it. These trials also only require bioequivalence rather than efficacy. This article gives a great rundown of $ACOG’s current pharmaceutical lineup as well as some breakdown on revenue projections for their new products. 


With prices trading at near recent lows, this could be a great time to scoop up some shares of $ACOG.


$ACOG is currently trading at $1.19 and is valued at $73.18M.


https://www.cantechletter.com/2021/10/alpha-cognition-could-have-a-best-in-class-alzheimers-drug-ia-capital-says/#

 
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities